Why Is CELLDEX THERAPEUTICS (CLDX) Stock Moving Today?

Celldex Therapeutics (CLDX) fell 11.56% to $33.51 in a single session, marking a sharp reversal for the biopharmaceutical company. The decline followed the release of positive Phase 3 trial results for barzolvolimab in chronic spontaneous urticaria, which were accompanied by growing concerns over safety data. While the drug met its primary and secondary endpoints, investor sentiment turned negative as reports highlighted potential safety issues that could delay regulatory approval.

What Happened

Celldex Therapeutics announced positive topline data from the EMBARQ-CSU1 and EMBARQ-CSU2 trials, showing barzolvolimab achieved a complete response rate of nearly 54% at 24 weeks in antihistamine-refractory chronic spontaneous urticaria patients. The company presented the results in a slide deck on September 22, 2026. However, media reports and analyst commentary quickly shifted focus to safety concerns, with Reuters noting that these issues overshadowed the clinical success. H.C. Wainwright called the safety concerns “misplaced” and reiterated a positive view, while Stifel and other analysts maintained Buy ratings. Despite this, the market reacted negatively, sending the stock sharply lower.

What The Data Shows

The stock has declined 8.1% over the last eight sessions, moving from $36.90 to $33.92. On September 22, it printed 22 fresh 52-week lows and only four 52-week highs, reflecting heightened volatility. The 52-week range remains $22.10 to $45.14. Celldex operates with a market cap of $3.0 billion but remains unprofitable, with a TTM EPS of -4.33 and TTM revenue down 97.3%. H.C. Wainwright raised its price target to $64 from $42, and both Morgan Stanley and Barclays increased their targets to $46 and $53, respectively.

What To Watch

Celldex is preparing for a 2027 FDA submission for barzolvolimab in chronic skin disease. Investors should monitor how regulatory agencies assess the safety data and whether the company can address concerns ahead of its filing.

Why is CLDX stock moving today?

CELLDEX THERAPEUTICS (CLDX) is drawing unusual attention today. Our newswire has captured 7 stories on CLDX across 5 sources in the last 36 hours, with AI sentiment reading mixed (avg 50/100). The most recent driver: "Celldex files automatic mixed securities shelf" (The Fly).

Is CLDX a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of CLDX coverage reads 50/100 over 7 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.